DOCSLIB.ORG

Improving Biopharmaceutical Production of Chinese Hamster Ovary Cells Using Targeted Genome Engineering Tools

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Improving Biopharmaceutical Production of Chinese Hamster Ovary Cells using Targeted Genome Engineering Tools A thesis submitted for the degree of PhD Dublin City University By Kevin Kellner, M.Sc. The research work described in this thesis was conducted under supervision of Dr. Nga Lao and Prof. Martin Clynes Dr. Niall Barron, University College Dublin National Institute for Cellular Biotechnology School of Biotechnology Dublin City University October 2018 ___________________________________________________________________________ I hereby certify that this material, which I now submit for assessment on the programme of study leading to the award of Ph.D. is entirely my own work, that I have exercised reasonable care to ensure that the work is original, and does not to the best of my knowledge breach any law of copyright, and has not been taken from the work of others save and to the extent that such work has been cited and acknowledged within the text of my work. Signed: ____________ (Candidate) ID No.: 14212905 Date: _______ ___________________________________________________________________________ I ___________________________________________________________________________ Dedicated to my beloved parents and friends ___________________________________________________________________________ II ___________________________________________________________________________ Acknowledgements Almost 5 years ago when I moved to Ireland to write my master’s thesis I would have never thought that I will stay a few years longer to do my PhD as well. With that I’d like to express my sincere gratitude to Dr. Niall Barron who gave me the chance to do my PhD in his lab. Thanks for never loosing your patience in every situation and for being always encouraging and positive even when experiments didn’t go well. On the same hand I’d like to say thanks to Prof. Martin Clynes who is the most supportive and good person I’ve ever met! Thanks also to Dr Nga Lao for supervising the last year of my thesis as well as managing that bunch of students in the lab - what would we do without your magic cloning hands? I would also like to thank the whole proteomics team with Dr. Paula Meleady, Dr. Micheal Henry, Orla Coleman, Dr. Shane Kelly and Dr. Mark Gallagher for helping and contributing so much towards my work. Thanks also to Dr. Clair Gallagher for spending a lot of hours on the FACS – still haven’t figured out your secret of keeping the patience! Of course, I would also like to thank all the postgrads and graduated doctors in our institute and School of Biotechnology for great lunch breaks, walks to Spar/Londis and coffee breaks. I am very glad to have made very good friends during my time in Ireland! Thanks Orla, Laura, Niamh, Giuseppe, Paul, Gemma, Andrew and Alan for the great company and laughs over the last few years. You have all been an amazing support over the last years especially in times of the reoccurring “PhD slumps”. Special thanks also to Justine Meiller, Mairead Callen, Emer Walsh, Gillian Smith and Carol McNamara for your support and help over the last years. The place would not run without you! Especially I would like to express my sincere gratitude to David Willaert for being the most amazing mentor and manager. I feel like I learned more over the last year as part of your team than during my entire PhD. Besides that, my last year wouldn’t have gone so smoothly without the motivating and inspiring speaches every second Friday. Thanks for always believing in me! I also want to thank everyone in the academia sales team for being outstanding and amazing - It was a pleasure to work with each of you and I am glad that I can call all of you friends by now. I would also like to express my deepest gratitude and appreciation to my best friends: Evelyn, Mischa, Caio. Nora and Maggy. Even though we did not see each other as often as I would have liked to during my time in Ireland I am deeply grateful that you have all been there for me at any time and that I could always count on you! Thanks also for some awesome visits and travels through Ireland and the very best support during times of discouragement but also excitement. There are no words which could express my gratitude to my beloved parents Angelika and Erwin for always supporting me at every stage during my life and not only throughout my PhD. Thanks for always having my back, inspring me to follow my dreams but also for pushing me always a little into the right direction! I could not have done it without you. ___________________________________________________________________________ III ___________________________________________________________________________ Scientific Talks, Posters, Publications and Graduate Training Elements Graduate Training Elements: - Leadership in Research - Biopharma Industry Regulations and Management - Posgraduate Tuter and Demonstrator - Professional Skills for Scientists Selected Scientific Talks: Cell Line Development and Engineering US 12-14th June 2018 in San Francisco as invited speaker. 28th European Society for Animal Cell Culture Technology UK (ESACT-UK) 10-11th January 2018 in Leeds, Poster Flash Presentation BioProduction Congress 2017 8-10th October 2017 in Dublin, Poster Flash Presentation Publications: Kellner K., Solanki A., Amann T., Lao N. and Barron N. (2018): "Targeting miRNAs with CRISPR/Cas9 to Improve Recombinant Protein Production of CHO Cells"; Methods Molecular Biology (David L. Hacker), 1850, - accepted for publication. Kellner K., Lao N., Coleman O., Meleady P. and Barron N. (2018): “Molecular impact of the microRNA-23 cluster on bioprocess relevant attributes of Chinese hamster ovary cells”; BMC Proceedings 2018 (12 - Suppl 1). ___________________________________________________________________________ IV ___________________________________________________________________________ Table of contents 1 Introduction ........................................................................................................................ 3 1.1 CHO cells in biopharmaceutical industry .............................................................. 3 1.1.1 Cell culture regimes and formats .................................................................... 5 1.1.2 CHO cell heterogeneity..................................................................................... 9 1.2 CHO cell engineering ............................................................................................. 11 1.2.1 Implication of ‘omic approaches .................................................................... 11 1.2.2 Apoptosis engineering .................................................................................... 12 1.2.3 Metabolic engineering ..................................................................................... 13 1.2.4 Secretion and molecular chaperone engineering ....................................... 14 1.2.5 Promoter engineering and optimisation of expression systems .............. 15 1.2.6 Glycosylation-engineering .............................................................................. 16 1.3 MicroRNAs ............................................................................................................... 18 1.3.1 Biogenesis of miRNAs .................................................................................... 20 1.3.2 MicroRNAs as potential tools for cell line engineering .............................. 24 1.3.3 Biological function of the miR-23-24-27 cluster and its role in disease .. 25 1.4 Targeted genome engineering tools .................................................................... 29 1.4.1 Sponge decoy technology for the stable or transient depletion of miRNAs 29 1.4.2 Clustered regularly interspaced short palindromic repeats (CRISPR) .... 31 1.4.3 CRISPR/Cas9 as targeted genome engineering tool ................................ 35 2 Aims of the project ......................................................................................................... 41 3 Material and Methods .................................................................................................... 43 ___________________________________________________________________________ V ___________________________________________________________________________ 3.1 Cell culture techniques ........................................................................................... 43 3.1.1 Ultrapure water................................................................................................. 43 3.1.2 Glassware ......................................................................................................... 43 3.1.3 Cell culture cabinet .......................................................................................... 43 3.1.4 Culturing of mammalian cells ......................................................................... 44 3.1.5 Cell lines and expressed products ................................................................ 48 3.1.6 Cryopreservation of cells ................................................................................ 48 3.1.7 Thawing of cryopreserved cells ..................................................................... 48 3.1.8 Lipid- and PEI-based transfection methods ................................................ 49 3.1.9 Physical transfection methods – Electroporation ....................................... 50 3.1.10 Generation of lentiviral particles ................................................................ 51 3.1.11 Limited
Recommended publications
  • CRISPR/Cas9-Mediated Knockout of DNAJC14 Verifies This Chaperone

    CRISPR/Cas9-Mediated Knockout of DNAJC14 Verifies This Chaperone

    GENOME REPLICATION AND REGULATION OF VIRAL GENE EXPRESSION crossm CRISPR/Cas9-Mediated Knockout of DNAJC14 Verifies This Chaperone as a Pivotal Host Factor for RNA Replication of Pestiviruses O. Isken,a A. Postel,b B. Bruhn,a E. Lattwein,a* P. Becher,b N. Tautza Downloaded from aUniversity of Luebeck, Institute of Virology and Cell Biology, Luebeck, Germany bUniversity of Veterinary Medicine Hannover, Institute for Virology, Hannover, Germany ABSTRACT Pestiviruses like bovine viral diarrhea virus (BVDV) are a threat to live- stock. For pestiviruses, cytopathogenic (cp) and noncytopathogenic (noncp) strains are distinguished in cell culture. The noncp biotype of BVDV is capable of establish- ing persistent infections, which is a major problem in disease control. The noncp biotype rests on temporal control of viral RNA replication, mediated by regulated http://jvi.asm.org/ cleavage of nonstructural protein 2-3 (NS2-3). This cleavage is catalyzed by the auto- protease in NS2, the activity of which depends on its cellular cofactor, DNAJC14. Since this chaperone is available in small amounts and binds tightly to NS2, NS2-3 translated later in infection is no longer cleaved. As NS3 is an essential constituent of the viral replicase, this shift in polyprotein processing correlates with downregula- tion of RNA replication. In contrast, cp BVDV strains arising mostly by RNA recombi- nation show highly variable genome structures and display unrestricted NS3 release. on August 6, 2019 by guest The functional importance of DNAJC14 for noncp pestiviruses has been established so far only for BVDV-1. It was therefore enigmatic whether replication of other noncp pestiviruses is also DNAJC14 dependent.
  • Computational Genome-Wide Identification of Heat Shock Protein Genes in the Bovine Genome [Version 1; Peer Review: 2 Approved, 1 Approved with Reservations]

    Computational Genome-Wide Identification of Heat Shock Protein Genes in the Bovine Genome [Version 1; Peer Review: 2 Approved, 1 Approved with Reservations]

    F1000Research 2018, 7:1504 Last updated: 08 AUG 2021 RESEARCH ARTICLE Computational genome-wide identification of heat shock protein genes in the bovine genome [version 1; peer review: 2 approved, 1 approved with reservations] Oyeyemi O. Ajayi1,2, Sunday O. Peters3, Marcos De Donato2,4, Sunday O. Sowande5, Fidalis D.N. Mujibi6, Olanrewaju B. Morenikeji2,7, Bolaji N. Thomas 8, Matthew A. Adeleke 9, Ikhide G. Imumorin2,10,11 1Department of Animal Breeding and Genetics, Federal University of Agriculture, Abeokuta, Nigeria 2International Programs, College of Agriculture and Life Sciences, Cornell University, Ithaca, NY, 14853, USA 3Department of Animal Science, Berry College, Mount Berry, GA, 30149, USA 4Departamento Regional de Bioingenierias, Tecnologico de Monterrey, Escuela de Ingenieria y Ciencias, Queretaro, Mexico 5Department of Animal Production and Health, Federal University of Agriculture, Abeokuta, Nigeria 6Usomi Limited, Nairobi, Kenya 7Department of Animal Production and Health, Federal University of Technology, Akure, Nigeria 8Department of Biomedical Sciences, Rochester Institute of Technology, Rochester, NY, 14623, USA 9School of Life Sciences, University of KwaZulu-Natal, Durban, 4000, South Africa 10School of Biological Sciences, Georgia Institute of Technology, Atlanta, GA, 30032, USA 11African Institute of Bioscience Research and Training, Ibadan, Nigeria v1 First published: 20 Sep 2018, 7:1504 Open Peer Review https://doi.org/10.12688/f1000research.16058.1 Latest published: 20 Sep 2018, 7:1504 https://doi.org/10.12688/f1000research.16058.1 Reviewer Status Invited Reviewers Abstract Background: Heat shock proteins (HSPs) are molecular chaperones 1 2 3 known to bind and sequester client proteins under stress. Methods: To identify and better understand some of these proteins, version 1 we carried out a computational genome-wide survey of the bovine 20 Sep 2018 report report report genome.
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
  • I ABSTRACT KHAREL, PRAKASH, Ph.D., December 2018 Chemistry

    I ABSTRACT KHAREL, PRAKASH, Ph.D., December 2018 Chemistry

    ABSTRACT KHAREL, PRAKASH, Ph.D., December 2018 Chemistry & Biochemistry RNA OXIDATION IN MULTIPLE SCLEROSIS NEURODEGENERATION (204 PP.) Dissertation advisor: Soumitra Basu An increase in the production of reactive oxygen species (ROS) and the inability of cellular machinery to adequately neutralize the ROS thus produced, lead the cells towards oxidative stress. ROS can damage all major classes of biomolecules including proteins, DNA and RNA. Recent findings show the evidence of high level of RNA oxidation in the neuronal cells of many neurological disorders suggesting a link between RNA oxidation and neurodegeneration. We have recently discovered the presence of extensive oxidative damage in the RNA molecules of neuronal cells in postmortem brains of multiple sclerosis (MS) patients. Working on the MS model system, we have established the identity of selectively oxidized mRNA molecules under MS microenvironment in human neuronal cells. Our study reveals that many of the mRNAs linked to various neurological pathways are selectively oxidized under oxidative stress. We have demonstrated the functional consequences of mRNA oxidation in two neuropathology related mRNAs (namely Nat8l and Nlrp3 mRNA). N-acetyl aspartate transferase 8 like protein (NAT8L) is a key trans-mitochondrial membrane protein that catalyzes the transfer of acetyl group from acetyl-CoA to aspartate to form N-acetyl aspartate (NAA) and transports NAA to neuronal cytoplasm. We have discovered that the oxidation in Nat8l mRNA molecule i results in the reduced expression of NAT8L enzyme. We also observed a reduced level of NAA present in the neuronal cells under oxidative stress. Using the neuronal tissue culture and MS animal model (cuprizone mouse model), we have established that a higher mRNA oxidation results in a reduced expression of NAT8L protein, which presumably contributes to the MS disease progression by weakening the myelin production machinery.
  • A Clinicopathological and Molecular Genetic Analysis of Low-Grade Glioma in Adults

    A Clinicopathological and Molecular Genetic Analysis of Low-Grade Glioma in Adults

    A CLINICOPATHOLOGICAL AND MOLECULAR GENETIC ANALYSIS OF LOW-GRADE GLIOMA IN ADULTS Presented by ANUSHREE SINGH MSc A thesis submitted in partial fulfilment of the requirements of the University of Wolverhampton for the degree of Doctor of Philosophy Brain Tumour Research Centre Research Institute in Healthcare Sciences Faculty of Science and Engineering University of Wolverhampton November 2014 i DECLARATION This work or any part thereof has not previously been presented in any form to the University or to any other body whether for the purposes of assessment, publication or for any other purpose (unless otherwise indicated). Save for any express acknowledgments, references and/or bibliographies cited in the work, I confirm that the intellectual content of the work is the result of my own efforts and of no other person. The right of Anushree Singh to be identified as author of this work is asserted in accordance with ss.77 and 78 of the Copyright, Designs and Patents Act 1988. At this date copyright is owned by the author. Signature: Anushree Date: 30th November 2014 ii ABSTRACT The aim of the study was to identify molecular markers that can determine progression of low grade glioma. This was done using various approaches such as IDH1 and IDH2 mutation analysis, MGMT methylation analysis, copy number analysis using array comparative genomic hybridisation and identification of differentially expressed miRNAs using miRNA microarray analysis. IDH1 mutation was present at a frequency of 71% in low grade glioma and was identified as an independent marker for improved OS in a multivariate analysis, which confirms the previous findings in low grade glioma studies.
  • 4-6 Weeks Old Female C57BL/6 Mice Obtained from Jackson Labs Were Used for Cell Isolation

    4-6 Weeks Old Female C57BL/6 Mice Obtained from Jackson Labs Were Used for Cell Isolation

    Methods Mice: 4-6 weeks old female C57BL/6 mice obtained from Jackson labs were used for cell isolation. Female Foxp3-IRES-GFP reporter mice (1), backcrossed to B6/C57 background for 10 generations, were used for the isolation of naïve CD4 and naïve CD8 cells for the RNAseq experiments. The mice were housed in pathogen-free animal facility in the La Jolla Institute for Allergy and Immunology and were used according to protocols approved by the Institutional Animal Care and use Committee. Preparation of cells: Subsets of thymocytes were isolated by cell sorting as previously described (2), after cell surface staining using CD4 (GK1.5), CD8 (53-6.7), CD3ε (145- 2C11), CD24 (M1/69) (all from Biolegend). DP cells: CD4+CD8 int/hi; CD4 SP cells: CD4CD3 hi, CD24 int/lo; CD8 SP cells: CD8 int/hi CD4 CD3 hi, CD24 int/lo (Fig S2). Peripheral subsets were isolated after pooling spleen and lymph nodes. T cells were enriched by negative isolation using Dynabeads (Dynabeads untouched mouse T cells, 11413D, Invitrogen). After surface staining for CD4 (GK1.5), CD8 (53-6.7), CD62L (MEL-14), CD25 (PC61) and CD44 (IM7), naïve CD4+CD62L hiCD25-CD44lo and naïve CD8+CD62L hiCD25-CD44lo were obtained by sorting (BD FACS Aria). Additionally, for the RNAseq experiments, CD4 and CD8 naïve cells were isolated by sorting T cells from the Foxp3- IRES-GFP mice: CD4+CD62LhiCD25–CD44lo GFP(FOXP3)– and CD8+CD62LhiCD25– CD44lo GFP(FOXP3)– (antibodies were from Biolegend). In some cases, naïve CD4 cells were cultured in vitro under Th1 or Th2 polarizing conditions (3, 4).
  • Manuscript for Proximity Interactome Analysis of Lassa

    Manuscript for Proximity Interactome Analysis of Lassa

    bioRxiv preprint doi: https://doi.org/10.1101/2021.07.16.452739; this version posted July 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. 1 Main Manuscript for 2 Proximity interactome analysis of Lassa polymerase reveals 3 eRF3a/GSPT1 as a druggable target for host directed antivirals. 4 Jingru Fang1,2, Colette Pietzsch3,4, George Tsaprailis5, Gogce Crynen5, Kelvin Frank Cho6, Alice 5 Y. Ting7,8, Alexander Bukreyev3,4,9, Erica Ollmann Saphire2* and Juan Carlos de la Torre1* 6 1 Department of Immunology and Microbiology, Scripps Research, La Jolla CA 92037 7 2La Jolla Institute for Immunology, La Jolla CA 92037 8 3Department of Pathology, University of Texas Medical Branch, Galveston, TX 77550 9 4Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX 77550 10 5Proteomics Core, Scripps Research, Jupiter, FL 33458 11 6Cancer Biology Program, Stanford University, Stanford, CA 94305 12 7Department of Genetics, Department of Biology and Department of Chemistry, Stanford 13 University, Stanford, CA 94305 14 8Chan Zuckerberg Biohub, San Francisco, CA 94158 15 9Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, 16 TX 77550 17 *Erica Ollmann Saphire; Juan Carlos de la Torre. 18 Email: [email protected] and [email protected] 19 Author Contributions: J.F., E.O.S., and J.C.T designed research; J.F. performed all non-BSL4 20 experiments and analyzed data; C.P.
  • (MINA) (NM 032778) Human Tagged ORF Clone Product Data

    (MINA) (NM 032778) Human Tagged ORF Clone Product Data

    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for RC212554L4 MINA53 (MINA) (NM_032778) Human Tagged ORF Clone Product data: Product Type: Expression Plasmids Product Name: MINA53 (MINA) (NM_032778) Human Tagged ORF Clone Tag: mGFP Symbol: RIOX2 Synonyms: JMJD10; MDIG; MINA; MINA53; NO52; ROX Vector: pLenti-C-mGFP-P2A-Puro (PS100093) E. coli Selection: Chloramphenicol (34 ug/mL) Cell Selection: Puromycin ORF Nucleotide The ORF insert of this clone is exactly the same as(RC212554). Sequence: Restriction Sites: SgfI-MluI Cloning Scheme: ACCN: NM_032778 ORF Size: 1392 bp This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 2 MINA53 (MINA) (NM_032778) Human Tagged ORF Clone – RC212554L4 OTI Disclaimer: The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. More info OTI Annotation: This clone was engineered to express the complete ORF with an expression tag. Expression varies depending on the nature of the gene. RefSeq: NM_032778.3, NP_116167.3 RefSeq Size: 2221 bp RefSeq ORF: 1395 bp Locus ID: 84864 UniProt ID: Q8IUF8 Protein Families: Druggable Genome MW: 52.5 kDa Gene Summary: MINA is a c-Myc (MYC; MIM 190080) target gene that may play a role in cell proliferation or regulation of cell growth.
  • Whole Exome Sequencing in Families at High Risk for Hodgkin Lymphoma: Identification of a Predisposing Mutation in the KDR Gene

    Whole Exome Sequencing in Families at High Risk for Hodgkin Lymphoma: Identification of a Predisposing Mutation in the KDR Gene

    Hodgkin Lymphoma SUPPLEMENTARY APPENDIX Whole exome sequencing in families at high risk for Hodgkin lymphoma: identification of a predisposing mutation in the KDR gene Melissa Rotunno, 1 Mary L. McMaster, 1 Joseph Boland, 2 Sara Bass, 2 Xijun Zhang, 2 Laurie Burdett, 2 Belynda Hicks, 2 Sarangan Ravichandran, 3 Brian T. Luke, 3 Meredith Yeager, 2 Laura Fontaine, 4 Paula L. Hyland, 1 Alisa M. Goldstein, 1 NCI DCEG Cancer Sequencing Working Group, NCI DCEG Cancer Genomics Research Laboratory, Stephen J. Chanock, 5 Neil E. Caporaso, 1 Margaret A. Tucker, 6 and Lynn R. Goldin 1 1Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; 2Cancer Genomics Research Laboratory, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; 3Ad - vanced Biomedical Computing Center, Leidos Biomedical Research Inc.; Frederick National Laboratory for Cancer Research, Frederick, MD; 4Westat, Inc., Rockville MD; 5Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; and 6Human Genetics Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA ©2016 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2015.135475 Received: August 19, 2015. Accepted: January 7, 2016. Pre-published: June 13, 2016. Correspondence: [email protected] Supplemental Author Information: NCI DCEG Cancer Sequencing Working Group: Mark H. Greene, Allan Hildesheim, Nan Hu, Maria Theresa Landi, Jennifer Loud, Phuong Mai, Lisa Mirabello, Lindsay Morton, Dilys Parry, Anand Pathak, Douglas R. Stewart, Philip R. Taylor, Geoffrey S. Tobias, Xiaohong R. Yang, Guoqin Yu NCI DCEG Cancer Genomics Research Laboratory: Salma Chowdhury, Michael Cullen, Casey Dagnall, Herbert Higson, Amy A.
  • Functional Interactomes of the Ebola Virus Polymerase Identified by Proximity Proteomics 2 in the Context of Viral Replication

    Functional Interactomes of the Ebola Virus Polymerase Identified by Proximity Proteomics 2 in the Context of Viral Replication

    bioRxiv preprint doi: https://doi.org/10.1101/2021.07.20.453153; this version posted July 21, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. 1 Functional interactomes of the Ebola virus polymerase identified by proximity proteomics 2 in the context of viral replication 3 Jingru Fang1,2, Colette Pietzsch3,4, George Tsaprailis5, Gogce Crynen6, Kelvin Frank Cho7, Alice 4 Y. Ting8,9, Alexander Bukreyev3,4,10*, Juan Carlos de la Torre2*, Erica Ollmann Saphire1* 5 1La Jolla Institute for Immunology, La Jolla CA 92037 6 2Department of Immunology and Microbiology, Scripps Research, La Jolla CA 92037 7 3Department of Pathology, University of Texas Medical Branch, Galveston, TX 77550 8 4Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX 77550 9 5Proteomics Core, Scripps Research, Jupiter, FL 33458 10 6Bioinformatics and Statistics Core, Scripps Research, Jupiter, FL 33458 11 7Cancer Biology Program, Stanford University, Stanford, CA 94305 12 8Department of Genetics, Department of Biology and Department of Chemistry, Stanford 13 University, Stanford, CA 94305 14 9Chan Zuckerberg Biohub, San Francisco, CA 94158 15 10 Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, 16 TX 77550 17 Correspondence: [email protected], [email protected], [email protected] 18 Lead contact: [email protected] 19 SUMMARY 20 Ebola virus (EBOV) critically depends on the viral polymerase to replicate and transcribe the viral 21 RNA genome.
  • The Viral Oncoproteins Tax and HBZ Reprogram the Cellular Mrna Splicing Landscape

    The Viral Oncoproteins Tax and HBZ Reprogram the Cellular Mrna Splicing Landscape

    bioRxiv preprint doi: https://doi.org/10.1101/2021.01.18.427104; this version posted January 18, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The viral oncoproteins Tax and HBZ reprogram the cellular mRNA splicing landscape Charlotte Vandermeulen1,2,3, Tina O’Grady3, Bartimee Galvan3, Majid Cherkaoui1, Alice Desbuleux1,2,4,5, Georges Coppin1,2,4,5, Julien Olivet1,2,4,5, Lamya Ben Ameur6, Keisuke Kataoka7, Seishi Ogawa7, Marc Thiry8, Franck Mortreux6, Michael A. Calderwood2,4,5, David E. Hill2,4,5, Johan Van Weyenbergh9, Benoit Charloteaux2,4,5,10, Marc Vidal2,4*, Franck Dequiedt3*, and Jean-Claude Twizere1,2,11* 1Laboratory of Viral Interactomes, GIGA Institute, University of Liege, Liege, Belgium.2Center for Cancer Systems Biology (CCSB), Dana-Farber Cancer Institute, Boston, MA, USA.3Laboratory of Gene Expression and Cancer, GIGA Institute, University of Liege, Liege, Belgium.4Department of Genetics, Blavatnik Institute, Harvard Medical School, Boston, MA, USA. 5Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.6Laboratory of Biology and Modeling of the Cell, CNRS UMR 5239, INSERM U1210, University of Lyon, Lyon, France.7Department of Pathology and Tumor Biology, Kyoto University, Japan.8Unit of Cell and Tissue Biology, GIGA Institute, University of Liege, Liege, Belgium.9Laboratory of Clinical and Epidemiological Virology, Rega Institute for Medical Research, Department of Microbiology, Immunology and Transplantation, Catholic University of Leuven, Leuven, Belgium.10Department of Human Genetics, CHU of Liege, University of Liege, Liege, Belgium.11Lead Contact. *Correspondence: [email protected]; [email protected]; [email protected] bioRxiv preprint doi: https://doi.org/10.1101/2021.01.18.427104; this version posted January 18, 2021.
  • Integrative Clinical Sequencing in the Management of Refractory Or

    Integrative Clinical Sequencing in the Management of Refractory Or

    Supplementary Online Content Mody RJ, Wu Y-M, Lonigro RJ, et al. Integrative Clinical Sequencing in the Management of Children and Young Adults With Refractory or Relapsed CancerJAMA. doi:10.1001/jama.2015.10080. eAppendix. Supplementary appendix This supplementary material has been provided by the authors to give readers additional information about their work. © 2015 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/29/2021 SUPPLEMENTARY APPENDIX Use of Integrative Clinical Sequencing in the Management of Pediatric Cancer Patients *#Rajen J. Mody, M.B.B.S, M.S., *Yi-Mi Wu, Ph.D., Robert J. Lonigro, M.S., Xuhong Cao, M.S., Sameek Roychowdhury, M.D., Ph.D., Pankaj Vats, M.S., Kevin M. Frank, M.S., John R. Prensner, M.D., Ph.D., Irfan Asangani, Ph.D., Nallasivam Palanisamy Ph.D. , Raja M. Rabah, M.D., Jonathan R. Dillman, M.D., Laxmi Priya Kunju, M.D., Jessica Everett, M.S., Victoria M. Raymond, M.S., Yu Ning, M.S., Fengyun Su, Ph.D., Rui Wang, M.S., Elena M. Stoffel, M.D., Jeffrey W. Innis, M.D., Ph.D., J. Scott Roberts, Ph.D., Patricia L. Robertson, M.D., Gregory Yanik, M.D., Aghiad Chamdin, M.D., James A. Connelly, M.D., Sung Choi, M.D., Andrew C. Harris, M.D., Carrie Kitko, M.D., Rama Jasty Rao, M.D., John E. Levine, M.D., Valerie P. Castle, M.D., Raymond J. Hutchinson, M.D., Moshe Talpaz, M.D., ^Dan R. Robinson, Ph.D., and ^#Arul M. Chinnaiyan, M.D., Ph.D. CORRESPONDING AUTHOR (S): # Arul M.